Martin Le • 1968 • Skedsmokorset • 14 roles • 5 shareholdings

This website uses cookies to enhance the user experience.

||

Roles

Management

Name	Role	Total operating income	Total equity	Shares
I INNOVA ACTIVE AS Closed	Managing Director/CEO	1,681,849	74,146	50 % indirectly
P PHARMA ACTIVE AS	Managing Director/CEO	275,000	10,158,505	50 % directly
F FRYDENLUND KVARTAL NÆRING 2 AS	Managing Director/CEO	950,000	634,054	50 % indirectly
N NORWEGIAN PHARMACY AS	Managing Director/CEO	86,262,315	202,531	50 % indirectly
3 365EIENDOM AS	Managing Director/CEO	-	1,577,181	50 % indirectly
S STJERNEAPOTEK GLASMAGASINET AS Closed	Managing Director/CEO	7,015,644	104,953	-
S STJERNEAPOTEK PALEET SHOPPING AS Closed	Managing Director/CEO	7,438,907	35,842	-

Boards

Name	Role	Total operating income	Total equity	Shares
I INNOVA ACTIVE AS Closed	Chairman	1,681,849	74,146	50 % indirectly
P PHARMA ACTIVE AS	Chairman	275,000	10,158,505	50 % directly
F FRYDENLUND KVARTAL NÆRING 2 AS	Chairman	950,000	634,054	50 % indirectly
N NORWEGIAN PHARMACY AS	Chairman	86,262,315	202,531	50 % indirectly
3 365EIENDOM AS	Chairman	-	1,577,181	50 % indirectly
S STJERNEAPOTEK GLASMAGASINET AS Closed	Chairman	7,015,644	104,953	-
S STJERNEAPOTEK PALEET SHOPPING AS Closed	Chairman	7,438,907	35,842	-

Last update: Apr 13, 2023

Related industries1

Goods and trade
/ Purchase and sale

Direct relationships1

HE
Huu Erica Thien Khuong1978
INNOVA ACTIVE AS, STJERNEAPOTEK GLASMAGASINET AS, PHARMA ACTIVE AS, FRYDENLUND KVARTAL NÆRING 2 AS, STJERNEAPOTEK PALEET SHOPPING AS, NORWEGIAN PHARMACY AS, 365EIENDOM AS

Shares owned by Martin Le

Name	Share class	Total operating income	Total equity	Share
P PHARMA ACTIVE AS	Ordinære aksjer	275,000	10,158,505	50 % directly
I INNOVA ACTIVE AS Closed		1,681,849	74,146	50 % indirectly
F FRYDENLUND KVARTAL NÆRING 2 AS		950,000	634,054	50 % indirectly
N NORWEGIAN PHARMACY AS		86,262,315	202,531	50 % indirectly
3 365EIENDOM AS		0	1,577,181	50 % indirectly

Limited to direct ownership positions of 0.5% or more.

Last update: Jun 2, 2025